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Integrated copy number and gene expression analysis
detects a CREB1 association with Alzheimer’s disease
Y Li1,10, CA Shaw2,10, I Sheffer1, N Sule3, SZ Powell4, B Dawson2,5, SNY Zaidi1, KL Bucasas6, JR Lupski2,7, KC Wilhelmsen8, R Doody1
and K Szigeti1,9
Genetic variation, both single-nucleotide variations and copy number variations (CNV), contribute to changes in gene
expression. In some cases these variations are meaningfully correlated with disease states. We hypothesized that in a
genetically heterogeneous disorder such as sporadic Alzheimer’s disease (AD), utilizing gene expression as a quantitative trait
and CNVs as a genetic marker map within the same individuals in the context of case–control status may increase the power to
detect relevant loci. Using this approach an 8-kb deletion was identified that contains a PAX6-binding site on chr2q33.3 upstream
of CREB1 encoding the cAMP responsive element-binding protein1 transcription factor. The association of the CNV to AD was
confirmed by a case–control association study consisting of the Texas Alzheimer Research and Care Consortium and NIA-LOAD
Family Study data sets.
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Introduction
Alzheimer’s disease (AD) is a devastating neurodegenerative
disorder affecting B5.4 million individuals in the United States
and is the most common cause of dementia in North America
and Europe.1–3 Genetic factors have an important role in the
pathogenesis of AD.4,5 Rare Mendelian forms of AD have
confirmed and elucidated pathways involved in amyloid
accumulation, but only account for a small percentage of
AD.6 GWAS studies have identified 10 susceptibility loci for
the more common, late-onset form of AD7 using single-
nucleotide polymorphisms (SNPs) as a genetic marker map.
The non-APOE loci account for 35% of the population
attributable fractions, suggesting that there is still missing
heritability.7 Published copy number variations (CNV) studies
in AD8–10,11 have focused on large events (4100 kb) to
achieve high confidence calls and performed the tests of
association on these events.
Genetic variation, both single-nucleotide variations
and CNV, contribute to changes in gene expression. In some
cases these variations are meaningfully correlated with
disease states.12 As GWAS studies are performed with
increasing sample sizes7,13–15 it is becoming clear that in
disorders with marked genetic heterogeneity where
the marker specific risk is low in case–control sets, it is
difficult to identify the true positives from the false positives
and to replicate the results.16,17 In addition, case–control
design in AD suffers from additional confounders, such as
misclassification bias due to age-dependent penetrance.
The approach of using gene expression data from pathologi-
cally ascertained cases and controls eliminates the
misclassification bias and gene expression serves as a
refined phenotype in a heterogeneous disorder, both increas-
ing the power to detect association signals. We hypothesized
that in a genetically heterogeneous disorder such as
sporadic AD, utilizing gene expression as a quantitative
trait (eQTL) and CNVs as a genetic marker map
within the same individuals may increase the power to
detect relevant loci, and by incorporating case–control status,
these loci will be candidates for case–control association
studies.
Materials and methods
Subject cohorts. The discovery cohort consisted of 22
pathological confirmed AD (mean age at death 80, range
61–93) temporal lobes and 15 control temporal lobes (mean
age at death 65, range 41–93). Human frozen temporal lobe
tissue was obtained from the Alzheimer’s Disease and
Memory Disorders Center tissue collection and the New
York Brain Bank. Neuropathological diagnosis was assigned
by board-certified neuropathologists. AD or control neuro-
pathology was confirmed by plaque and tangle assessment
and Braak staging. The brain cohort was exempt from IRB
approval as the specimens were deidentified.
The case–control association study consisted of the Texas
Alzheimer Research and Care Consortium (TARCC) and the
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NIA-LOAD Family Study (LOAD) probands http://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000168.v1.p1.)
The TARCC data set including 381 Caucasian subjects with
probable AD and 191 neuropsychologically tested normal
controls.18 Probable AD was assigned by NINCDS-ADRDA
criteria after consensus review.19 Controls were recruited at
each participating site by the same inclusion criteria, including
age over 55 years, male and female, unrelated to AD subjects,
CDR global score 0, normal performance on activities of daily
living, and all information was obtained from surrogate
historian. After enrollment all control subjects underwent
neuropsychological testing including assessment of global
cognitive functioning (MMSE and CDR), attention (Digit Span
and Trails A), executive function (Trails B and Clock Drawing),
memory (WMS Logical Memory I and WMS Logical Memory
II), language (Boston Naming and FAS Verbal Fluency),
Premorbid IQ (AMNART), Visuospatial Memory (WMS-Visual
Reproduction I and II), Psychiatric (Geriatric Depression
Scale; Neuropsychiatric Inventory-Questionnaire) and Func-
tional assessment (Lawton-Brody ADL: PSMS, IADL). Control
subjects showing impairment were excluded from the control
cohort after consensus review.
The Institutional Review Board of BCM and all participating
sites approved the study. Informed consent was obtained
from all subjects before inclusion. Genomic DNA was isolated
from whole blood by the Puregene DNA isolation kit (Qiagen,
Germantown, MD, USA) according to the manufacturer’s
instructions.
Isolation of DNA and RNA from brain tissue, expression
profiling and genotyping. DNA was prepared with QIAamp
DNA mini kit (Qiagen) according to the manufacturer’s
instructions. For RNA preparation, brain tissue was homo-
genized with a tissue homogenizer in Trizol (Invitrogen,
Madison, WI, USA) and purified with Rneasy mini kit
(Qiagen). DNA and RNA QC criteria for proceeding to array
experiments were 260/280 nm 1.6–1.8 for DNA and 1.9–2.0
for RNA, 260/230 nm 42.0 for DNA and 41.5 for RNA by
Nanodrop 1000 (Wilmington, DE, USA). RNA quality was
further assessed by calculating RIN (RNA integrity number)
with Agilent 2100 (Santa Clara, CA, USA) Bioanalyzer
(Microarray core facility, Baylor College Medicine). Sample
was entered to expression array experiment if RIN 44
(range 4.3–6.9).
Microarray expression profiling was performed on the
Illumina Human-6 V3 BeadChip (Illumina, San Diego, CA,
USA) (Supplementary information). Genotyping was per-
formed on the Genome-Wide Human SNP Array 6.0
(Affymetrix, Santa Clara, CA, USA) according to the manu-
facturer’s instructions (Supplementary information). Long-
range PCR was designed for the deletion genotyping
(Supplementary information). APOE genotyping was per-
formed according to manufacturer‘s instruction with real-time
PCR using custom TaqMan probes (Applied Biosystems,
Carlsbad, CA, USA) (Supplementary information).
Analysis of array data
Genome-wide CNV inference for the initial analysis. CNV
states for each subject were determined by segmentation of
the Genome-wide Human SNP Array 6.0 (Affymetrix) data
with the Hidden Markov Model algorithm in the Genotyping
Console 3.0 software (Affymetrix, Santa Clara, CA, USA)
package using detection threshold of 1 kb.
Expression data. Normalized expression array values were
obtained by processing Illumina BeadStudio summary data
using the VST transform method as implemented in the lumi
R package,20,21 which performs variance stabilization on the
low level data to achieve normal distribution. We validated
the normal distribution for the significant probes by visualiz-
ing residual plots. We also required Illumina BeadStudio
probewise detection P-values o0.05 to be considered in the
expression analysis. To ensure cross array comparability
after the detection filter quantile normalization was applied to
the VST summaries across all subjects.
Definition of CNV expression. The UCSC browser track was
utilized for mapping every probe to the human genome Build
36; 500 Kb padding was added on each side of the
expression probe (1 Mb total window) and any CNV calls
overlapping the 1 Mb window was associated with that probe.
The 500 kb was selected based on previously published
data22 suggesting that within this distance the likelihood of an
effect of a SNP on gene regulation is over 99%. All CNV calls
were tabulated as integer values 0 (homozygous loss,
extremely rare), 1 (single-copy loss) 2 (diploid) 3 (gain) and
4 (multi-gain) within 500 kb upstream and downstream from
each transcript for each person. To avoid distortions for rare
multi-copy gains or losses, the encoding of one for both
homozygous and hemizygous loss, two for normal CNV state
and three for gain CNV state was used.
Statistical analysis of the discovery cohort incorporating
expression, disease state and CNV information. The follow-
ing filters were applied to reduce the data set to meaningful
comparisons for the hypothesis: (i) expressed in brain (bead
level data detection Po0.05), (ii) differentially expressed
between cases and controls (t-test, Po0.05) and (iii) CNV
events in at least two individuals that are within 1 Mb of the
expression probe (frequency 40.05) to avoid spurious
associations caused by single events at the extremes of
the expression spectrum.
The null hypothesis is that the difference in expression
between cases and controls does not correlate with cis-CNV
state. Analysis of covariance (ANCOVA) was performed for
each expression probe where a linear effect for CNV together
with a shift term for case–control status was estimated by
least squares. The fraction of variation (partial R^2) attribu-
table to CNV state was assessed by taking the ratio between
the regression sum of squares for the CNV information to the
regression sum of squares for the full model. The F-statistic
and a corresponding P-value were determined by dividing the
mean square regression for CNV by the mean square error of
the full ANCOVA. This analysis can be performed by selecting
corresponding entries from the ANCOVA table from the
appropriate statistical software.
Case–control association study. Subsequently to test the
hypothesis whether this association could be detected in a
larger case–control study we performed a metaanalysis of
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the TARCC cohort and the publicly available NCRAD-LOAD
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_
id=phs000168.v1.p1) Caucasian probands (N¼ 2166). The
TARCC cohort was genotyped on the Affymetrix 6.0 array.
The genotype calls were generated by the GoldenHelix
software. The NCRAD-LOAD data were analyzed by the
Beadstudio software for log2ratio calculation and the
genotype calls were based on the log2ratio distributions by
inspection of the kernel density estimate of log2ratios and
identification of cutpoints that distinguished the three
genotype classes. Fisher’s exact test was calculated for the
TARCC, LOAD and the metaanalysis. In addition, we
developed a factorial model using logistic regression with
the logitlink function, which allowed the addition of sex and
age as covariates. Odds ratio was calculated for the deletion
carrier status in the metaanalysis by collapsing the homo-
zygous and heterozygous deletion carriers.
Results
Thrity-seven expression arrays passed QC criteria and 31
genotyping arrays were adequate for copy number analysis.
Consideration was limited to (i) CNVs where at least two
subjects had other than two copies of the region (locus-
specific frequency 40.05), (ii) genes where expression level
could be distinguished from background with P-value of
o0.05 and that were within 500 kb upstream and downstream
from each CNV. These interval parameters detect 90% of
interactions extrapolated from SNP data.23 Combining the
CNV variation and gene expression filters resulted in 2455
probes corresponding to 2063 genes to be considered in our
eQTL and CNV integrated analysis. As the aim is to identify
genes that have an association with disease state, the
analysis was applied to genes (probes) that are differentially
expressed between AD cases and controls (Po0.05). Five
hundred seventy-four probes corresponding to 531 genes
were differentially expressed between cases and controls.
These genes were tested for whether expression was
correlated with CNV genotype status. Regression results
(F-statistic P-values) for the component of variance explained
by CNV in the ANCOVA are depicted in the Manhattan plot
(Figure 1). Six probes had P-values of o0.001. These probes
also had over 50% of the variance in expression explained by
the ANCOVA attributable to CNV. (Table 1) The top hit
ARL17P1 corresponds to CNVR 7114.8 and CNVR 7114.10
(http://www.sanger.ac.uk/cgi-bin/humgen/cnv/42mio/down-
loadBigDB.cgi),24 and the subsequent three probes coding
CREB1 and FAM119A correspond to CNVR 1123.1. These
latter three probes have similar P-values and identical
slopes and thus appear to represent a triplicate experiment.
The two additional genes identified on chromosome 1 are
SDF4 and NBPF10. SDF4 does not have a known
corresponding CNV and NBPF10 corresponds to CNVR
93.13 and CNVR 94.3. The distribution of the expression
data is represented with box plots for the three probes on
chromosome 2 in Figure 2. Multiple testing corrections for
this analysis are confounded by the potential of linked
probes to have correlated results because they share the
associated CNV resulting in overcorrection. An alternative
approach is to calculate the probability of a run of 3 in a row
in 574 trials where 6/574 are positives, which is 0.0006. The
assumption was made that the modest number of linked
probes represents replicate experiments examining the
association with CNV state instead of independent experi-
ments; any result identified in the eQTL study was
anticipated to be confirmed by tests in a larger case–
control cohort. Gene expression levels were validated by
TaqMan assay for CREB1 (Supplementary Figure 1). The
differential expression of CREB1 between cases and
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Figure1 The Manhattan plot depicts the  log10p for the F-statistic
corresponding to the portion of variation of expression explained by copy number
variation (CNV) state in the analysis of covariance (ANCOVA) in the reduced data
set after the filters (N¼ 574). The chromosomes are shaded alternately and each
expression probe is represented by a dot. Probes with Po0.001 were considered
for a case–control association study (red).
Table 1 Regression results (F-statistic P-values) for the component of case–control variance explained by CNV in the ANCOVA
Probe_Id ILMN_Gene Chromosome Start Stop pADCNV FracColinear nVariants
ILMN_1698680 ARL17P1 17 41732281 42012404 0.0004 0.90 22
ILMN_2049364 FAM119A 2 208154323 208198218 0.0054 0.77 9
ILMN_2334242 CREB1 2 208102930 208171815 0.0066 0.70 9
ILMN_2334243 CREB1 2 208102930 208171815 0.0070 0.68 9
ILMN_1696065 SDF4 1 1142150 1157310 0.0074 0.64 4
ILMN_2155719 NBPF10 1 16762998 146690991 0.0098 0.53 31
Abbreviations: ANCOVA, analysis of covariance; CNV, copy number variation.
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(#10) (GSE15222); the AD cases had higher expression
levels compared with the normal controls (t-test, P¼ 1.36
 10 18) (Supplementary Figure 2).
The case–control cohort (1230 AD subjects and 936 normal
controls) consisted of the TARCC data set (381 cases and 191
controls) and the LOAD Caucasian probands (N¼ 848) and
Caucasian unrelated controls (N¼ 745). First we studied the
TARCC data set as it had adequate coverage of the candidate
regions to perform segmentation. The cohort characteristics
are summarized in Supplementary Table 1. In the chro-
mosome 2 region the contiguous significant P-values of
the overlapping sliding windows delineate the position of the
deletion (CNVR 1123.1) detected in the discovery cohort. The
association between copy number and case–control status for
the sliding windows across the 1 Mb regions are depicted in
Table 2 for the chromosome 2 region. The genomic locations
of the associated CNVRs are depicted by the bolded probe
identifiers in each table. The other regions which were not
considered significant after correction for multiple compar-
isons are summarized in Supplementary tables 2–4. As the
LOAD genotyping platform offered a limited number of probes (7),
the segmentation algorithms had limited utility.
Second, in order to further validate the association of CNVR
1123.1 the association was tested after generating CNV calls
(CN 0, 1 and 2 quantitating homozygous deletion, hetero-
zygous deletion and normal diploid state) in both the TARCC
and LOAD cohorts. The 8 kb deletion was covered with 23
probes on the Affymetrix array and 7 probes on the Illumina
array. Genotype calls were based on the log2ratio distribu-
tions by inspection of the kernel density estimate of log2ratios
and identification of cutpoints that distinguished the three
genotype classes. Long-range PCR confirmed the chip based
genotyping of CNVR 1123.1 for 277 TARCC samples in which
DNA was available for this study. The genotyping accuracy of
the Affymetrix array is 96%. Typical genotyping results are
depicted in Figure 3. The frequencies of the homozygous and
heterozygous deletion samples did not defer between
the TARCC and LOAD cohorts genotyped on the Affymetrix
and Illumina platforms, respectively (Supplementary Table 5).
The PCR validation and similar allele frequencies suggest that
the genotyping is accurate. The Fisher’s exact test resulted in
a P-value of 0.008 in the combined set and the Fisher’s exact
test was significant in both the TARCC (for both the Affymetrix
and the PCR (Supplementary Table 7) based genotype
calls) and LOAD cohorts when analyzed separately
(Supplementary Table 6). The odds ratio for the deletion
carrier status (collapsed homozygous or heterozygous dele-
tion) was calculated for the metaanalysis (OR 1.23 (1.02–
1.49)). Furthermore, we applied a factorial model in the
replication set (1230 AD subjects and 936 normal controls) to
study the effects of age and gender as covariates. The
association remained significant after adding age and gender
into the model (P¼ 0.03). APOE data was available for the
TARCC set; the regression model remained significant for
CNV effect (Table 3).
Third, we studied whether this association is expected to be
detected in GWAS studies. SNP association with case–control
status was explored using the genotypes of 24 SNPs in the
region using the TARCC cohort (Supplementary table 8). The
strongest linkage disequilibrium with CNVR 1123.1 was for
rs2113383 and rs7561038 with r2 value of 0.39 and 0.22,
respectively (Supplementary figure 3). These two SNPs
although did not survive multiple testing correction, had the
strongest level of association with case–control status (cor-
rected P¼ 0.26 and 0.055, respectively). To delineate the
potential mechanism for the deletion event the breakpoint of five
homozygous deletion samples was sequenced. Interestingly
the breakpoint sequences were identical (Figure 3). In the
breakpoint sequence an inserted sequence was identified
400 kb downstream from the deletion (Figure 3).
Discussion
Transcribed sequences were identified with evidence of
differential expression in the temporal lobe of post mortem
patients with and without AD in which a significant portion of
the variation in gene expression was attributable to CNV
(Figure 1 and Table 1). Five genes were both differentially
expressed between cases and controls and had 450% of the
variance explained attributable to the cis-CNV state. Three of
the six probes are adjacent to CNVR 1123.1 and fall into a
linked region in AD on chromosome 2. Two of these probes
are replicates of CREB1 and the third probe is FAM119A, a
gene adjacent to CREB1. The sign and size of the regression
coefficients and P-values are similar suggesting that the
association is observed in triplicate. CREB1 has been
implicated in memory by multiple lines of evidence.25,26
The associated deletion, CNVR 1123.1 has been reported
and validated in endeavors to catalog CNVs genome-
wide (http://www.sanger.ac.uk/cgi-bin/humgen/cnv/42mio/
Figure 2 The box plots depict the expression levels in Alzheimer’s disease (AD) and controls by copy number state (1 or deletion and 2 or diploid) for the three probes
corresponding to the two adjacent genes (CREB1 and FAM199A) on chromosome 2. These probes represent a triplicate experiment as they are associated with the same
copy number variation (CNV; CNVR 1123.1) and have similar expression patterns. The association of CNVR 1123.1 with AD was confirmed in the case–control association
study.
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downloadBigDB.cgi). Genotyping was confirmed by long-
range PCR.
Subsequently, the associated CNVs were followed-up in a
case–control association study. The case–control association
study confirmed that harboring the CNVR 1123.1 deletion
increases the risk of AD with an odds ratio of 1.23 (1.02–1.49).
The TARCC data set was used (i) to perform a SNP
association study with SNPs in the same haplotype block
with CNVR 1123.1, and (ii) to evaluate linkage disequilibrium
between the SNPs and the deletion in the haplotype block.
None of the SNPs tag the deletion perfectly (r2 max 0.39) and
while rs2113383 and rs7561038 showed an association with
the disease phenotype it was weaker than that of the deletion
and did not survive multiple testing correction.
In order to elucidate the mechanism of rearrangement,
the breakpoints of five homozygous deletion samples were
sequenced. Interestingly the breakpoint sequences were
identical. The breakpoint sequence suggests a replication-
dependent mechanism27 as the inserted sequence was
identified 400 kb downstream from the deletion making
recurrent events less likely. The linkage disequilibrium
map and the identical breakpoints suggest that the
deletion occurred on the ancestral haplotype. As a result
the deletion association is a haplotype association where the
haplotype is tagged by a single marker (CNVR 1123.1). This
haplotype structure likely increased the statistical power and
allowed the detection of the association signal. GWAS studies
using single SNPs may have not been able to detect this
Table 2 Association results of the probes of the 1 Mb region surrounding CREB1 and FAM199A
Predictor Chromosome Position Trend P Trend R Trend Bonferroni P
CN_845075 2 207622072 0.2977 0.0435 1
SNP_A-1966626 2 207663403 0.5974 0.0221 1
SNP_A-1887677 2 207665482 0.1818 0.0558 1
CN_845090 2 207673903 0.3442 0.0395 1
SNP_A-8671717 2 207732485 0.2332 0.0498 1
SNP_A-8465960 2 207733395 0.3069 0.0427 1
SNP_A-2028696 2 207781838 0.2920 0.0440 1
CN_845130 2 207795277 0.4051 0.0348 1
SNP_A-2218992 2 207833393 0.3363 0.0402 1
SNP_A-2136852 2 207858744 0.5511 0.0249 1
CN_847305 2 207994945 0.5556 0.0246 1
CN_847318 2 208027023 0.7844 0.0114 1
SNP_A-8299273 2 208048623 0.4719 0.0301 1
SNP_A-8494281 2 208049459 0.7825 0.0115 1
SNP_A-8483760 2 208053385 0.6240 0.0205 1
CN_847334 2 208058167 0.8857 0.0060 1
CN_847330 2 208058424 0.3522 0.0389 1
CN_847331 2 208058480 0.4080 0.0346 1
CN_847332 2 208058495 0.4590 0.0309 1
CN_847333 2 208058552 0.5312 0.0262 1
CN_847335 2 208058859 0.4634 0.0306 1
SNP_A-8302877 2 208058999 0.5217 0.0268 1
CN_847336a 2 208063145 0.3171 0.0418 1
CN_847337a 2 208063188 0.0625 0.0778 1
CN_847338a 2 208063411 0.0006 0.1436 0.0293
CN_847339a 2 208063571 0.0004 0.1482 0.0194
CN_847340a 2 208063929 0.0011 0.1368 0.0529
CN_847341a 2 208063951 0.0008 0.1406 0.0380
CN_847342a 2 208063985 0.0006 0.1437 0.0290
CN_847343a 2 208064228 0.0003 0.1497 0.0169
CN_847348a 2 208066987 0.0004 0.1469 0.0220
CN_847350a 2 208067258 0.0006 0.1437 0.0291
CN_847351a 2 208067382 0.0018 0.1306 0.0888
CN_847352a 2 208067569 0.0008 0.1402 0.0396
CN_847353 2 208067709 0.2648 0.0466 1
CN_847354 2 208067752 0.3293 0.0408 1
CN_847355 2 208067793 0.0191 0.0979 1
CN_847358 2 208068379 0.0853 0.0719 1
CN_847359 2 208068455 0.1653 0.0580 1
CN_847360 2 208068501 0.2382 0.0493 1
CN_847361 2 208069832 0.4702 0.0302 1
CN_847362 2 208069845 0.3084 0.0425 1
SNP_A-8295329 2 208202479 0.6110 0.0212 1
CN_849537 2 208223269 0.3599 0.0382 1
SNP_A-1953258 2 208243710 0.3204 0.0415 1
CN_849545 2 208251726 0.4416 0.0321 1
SNP_A-8545295 2 208263276 0.2956 0.0437 1
CN_849558 2 208293433 0.3533 0.0388 1
SNP_A-4247203 2 208503576 0.2214 0.0511 1
CN_849623 2 208508184 0.7706 0.0122 1
Abbreviations: CN, copy number; SNP, single-nucleotide polymorphism.
aThe highlighted probe names mark the genomic location of the CNVR detected in the discovery cohort.
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association signal as they did not incorporate the haplotype
information.
Variation CNVR 1123.1 400 Kb upstream of CREB1
encompasses a conserved PAX6-binding site,28 which could
explain the altered gene expression. PAX6 has been
implicated in the development of the eye and nervous
system,29,30 and effects of PAX6 mutations were associated
with eye developmental anomalies31and developmental
anomalies of the brain.32 The effect of loss of this specific
PAX6-binding site has not been studied, and the regulation of
CREB1 and FAM119A by PAX6 has not yet been described to
our knowledge. Further experimental work will be needed to
delineate the relationship between PAX6 and CREB1 or
FAM119A. Interestingly, other deletion CNVs in noncoding
regions have recently been linked to disease, even common
disease.33 A deletion polymorphism upstream of IRGM was
found to alter IRGM expression and explained the known
association signal in Crohn’s disease.34
The expression of FAM119A adjacent to CREB1 was also
significant in the analysis of CNV-gene expression interaction
accounting for the disease state; therefore, its potential
role cannot be excluded. FAM119A is a predicted
Figure 3 Genotyping, genomic context and breakpoint analysis of CNVR 1123.1. (a) Genome-Wide Human SNP Array 6.0 is presented as plot of normalized probewise
log2ratio data in the three panels for diploid, heterozygous and homozygous deletion carriers (CN¼ 2,1,0). (b) Electrophoresis of long-range PCR products of the same
samples. The heterozygous deletion carrier generates two PCR products from the normal and the deletion alleles, respectively. (c) The genomic context of the deletion (black)
is outlined in relation to the two genes CREB1 (light purple) and FAM119A (dark purple) in cis. The deletion encompasses a conserved PAX6-binding site (orange arrow). The
breakpoint for the deletion was sequenced in five individuals and detected the same inserted sequence at the breakpoint. The inserted sequence is present 400 kb
downstream from the deletion suggesting a replicative mechanism for rearrangement.
Table 3 Logistic regression on the dichotomized data (deletion or 1 copy and normal or 2 copies) of CNVR 1123.1, incorporating the number of APOE4 alleles and
gender to the model. The genotypes were validated by long-range PCR
Regressor Coefficient Standard
error





APOE E4_count 1.145 0.1657 6.1102 e–14 3.14 2.27 4.35 2.38e–14
Gender 1¼M, 2¼F  0.425 0.1972 0.0300 0.65 0.44 0.96 0.0286
CN_847343 0.729 0.2227 0.0008 2.07 1.34 3.21 0.0001
Abbreviations: CN, copy number; OR, odds ratio.
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methyltransferase with unknown function. CREB1 belongs to
the CREB family of leucine-zipper transcription factors that
have a central role in cell signal transduction. In a molecular
triangulation analysis in AD with APOE, APP, PSEN1 and 2,
CREB1 has been predicted as one of the top 10 network
nodes.35 Disruption of CREB1 in a mouse model showed
neurodegeneration in the hippocampus.36 Expression of a
constitutively active form of CREB1 in mice interfered with
retrieval of spatial information.37 CREB1 is regulated by
alternative splicing and alternative promoters in Aplysia.38,39
This study presents an approach to detect a phenotypically
relevant association in a genetically heterogeneous disorder
using gene expression as an eQTL and genetic markers
(CNVs in this case) in the same individuals. One limitation of
the study is the use of post mortem human brain tissue in the
discovery cohort. Interestingly, three probes corresponding to
two genes showed very consistent coefficients and P-values;
this suggests that degradation was not a major problem at
least for these two genes. In addition, the case–control asso-
ciation study used only CNV genotypes derived from blood,
with independent methods and statistical approaches, and
confirmed the association.
The increased power of the discovery cohort to detect the
association is attributable to multiple factors: (i) elimination of
misclassification bias by using pathologically confirmed cases
and controls, (ii) refined phenotype by using gene expression
as eQTL and (iii) deriving genotype and expression data from
the same individual allowing for direct correlation. GWAS
studies with increasing sample sizes7,13–15 suggest that
disorders with marked genetic heterogeneity where the
marker specific risk is low in case–control sets, may have
limitations to detect and replicate association signals.16,17 This
approach may complement the robust GWAS studies to
identify biologically relevant loci in this devastating disease
with the ultimate goal to find intervention.
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